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ABSTRACT 
Introduction: Colorectal cancer (CRC) is associated with liver metastases up to 35% of cases. Even after performance 
of liver surgery with curative intent and absence of extra-hepatic involvement, recurrence is frequent. Therefore, the 
identification of factors associated with recurrence and disease-free survival (DFS) could provide better selection of 
candidates for liver surgery.  
Patients and methods: Patients submitted to liver surgery for colorectal liver metastases (CRLM), in São João 
Hospital Center (CHSJ), with 5-years survival and no extra-hepatic disease were studied. Data was collected and 
analysed to identify recurrence and DFS associated factors.  
Results: Recurrence occurred in 20 patients (52.63%) and 27 patients (71.05%) are alive and in remission with a DFS 
mean of 73 months. Statistical significance was found for early relapse associated with left side colon cancer (p < 
0.05) and late recurrence with positive margins (p < 0.043). Also, patients with less than 5 metastases had at least 
double DFS (p < 0.033).  
Conclusion: DFS is optimized when less than 5 lesions are present. Faster relapses occur in right colon cancer, 
although DFS was similar independently of primary´s tumour site. It is important to increase size sample and compare 
to those without 5-year survival for further conclusions. 
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INTRODUCTION 
 Colorectal cancer (CRC) remains the third cause of malignancy death worldwide 1,2. There hasn´t been found 
any association in gender but it´s well recognise that men present higher mortality and incidence rates, although rate 
of CRC deaths appear similar between both genders 2,3. Primary prevention is the first step towards several recognized 
risk factors, such as diet, physical activity, weight, smoking and alcohol 4. Most developed countries divulged 
screening progress, especially for individuals at risk (Inflammatory Bowel Disease and personal or family history of 
CRC), promoting early detection, as well as better and improved treatments that have allowed an increase of Overall 
Survival (OS) 2,3,5. 
 When suspicion of CRC, full work up, including thoracic/abdominal/pelvic computed tomography (CT), 
should be performed and in doubt an MRI, in order to verify resectability of primary tumour, liver metastases and the 
existence of extra-hepatic disease 4. The use of enhance imaging techniques allows the identification of colorectal liver 
metastases in 35% of cases 6–8. Furthermore, synchronous metastases are in a majority of cases, 70-80%, confined to 
the liver 9. And eventually, more than half of CRC patients will develop liver metastases 9,10. Until now, hepatic surgery 
as proven to be the most effective treatment increasing OS 4,11–14 with mortality rates after hepatic surgery described 
as lower than 5% 14–16 and 5-years survival between 16-74% according to Kansas et al review and meta-analysis 12.  
 Nowadays, new therapies such as transarterial chemoembolization (TACE); systemic chemotherapy, with or 
without biologic agents; radioembolization with Yttrium-90 (useful to refractory disease) and radiofrequency ablation 
(RFA) have been used in association with surgery or even as a substitute for those inapt for surgery 4,17,18. All local 
therapies with no exception have been proven to be inferior to surgery when used alone 4,5,19. However, if the use of 
some of these therapies need more studies to support more consistent applications, the use of chemotherapy has been 
widely established 4. Even though, perioperative chemotherapy in resectable liver metastases is still somewhat 
debatable and should be applied individually to patient characteristics 5,20, it achieves great importance in converting 
irresectable liver metastases in resectable ones, especially because the majority of patients appear to have irresectable 
lesions 4,5,17,21,22. It has been described that patients with successful conversion of irresectable liver metastases can even 
achieve 33 to 76% survival at 5-years 23–25.  
Given the evolve of all medical areas (pathology, oncology, radiology and surgery) and the different 
therapeutic options available is extremely important that this patients should be referred to centers with 
multidisciplinary teams that are better prepared to provide better decisions for individual patients regarding 
management and treatment, decreasing delays, costs and increasing OS 5,19,26. 
  
If, on one hand, 5-years survival has been increasing due to a better medical treatment-management, on the 
other hand recurrence is still frequent and affects around 70% within less than 2-years 27. And so, a close up follow up 
is needed for patients treated for colorectal liver metastases (CRLM). This is usually done by measuring 
carcinoembryonic antigen (CEA) levels and performance of CT scan on  regular basis, since they´re the most cost-
effective for detecting recurrence 28. Still, a close-up surveillance is necessary and it is also imperative that we 
understand which factors could contribute to a intra or extra-hepatic recurrence, in order to improve patient treatment 
and patient selection.   
The aim of the present study is to study factors that could correlate to recurrence and DFS, in patients that are 
alive 5-years after CRLM resection.  
PATIENTS AND METHODS 
 All patients submitted to resection of CRLM in the Department of Hepatobiliary Surgery of São João Hospital 
Center (CHSJ), from 2006 to 2012, were identified in the Department´s database.  
 One by one, each patient was analysed, being selected only those with the following characteristics: 
• 5-year follow-up in CHSJ 
• No extra-hepatic disease 
• Hepatic resection with curative intent 
Data for these patients were afterwards extracted from the Hospital´s database, which included clinical records 
from medical consultations (oncology, colon surgery, hepatic surgery), imaging exams (CT), full blood workup, 
anatomopathological results and surgical registries. No patients or family patients were contacted during the fulfil of 
this study. And all measures were taken protecting the anonymity of these patients. This study was approved by the 
Ethical Comity (CES) of CHSJ, number 270/17.  
Patient selection is represented in Figure 1. 
The following data was searched: age, gender, site and histopathology from the primary tumour, time of 
hepatic metastases and characteristics (size, number and localization), preoperative CEA levels, hepatic surgical 
resection, complications, time of recurrence and time of disease free.  
Patients with the primary tumour located less than 15 cm from the anal margin were defined as rectum, as 
designed in the nomenclature of the Portuguese Society of Surgery. Right side colon cancer (RCC) was considered 
between cecum and proximal transverse and left side colon cancer (LCC) included distal transverse, descending colon 
  
and sigmoid. 
Complete lymphadenectomy was considered when at less 12 lymph nodes were removed. 
 DFS was considered the time interval between first liver resection and secondary recurrence of CRC (colon, 
liver, lung or other extra-hepatic sites). Early relapse was defined as within less than 12 months after CRLM resection. 
 Data were pooled and analysed using SPSS v. 25 software. Numerical variables were described using mean 
or median with their dispersion measures (standard deviation and 95% confidence interval or 5 and 95 percentiles). 
Categorical variables were described in relative frequencies. In the comparison between groups, independent t-student, 
ANOVA or Pearson´s Chi-Square tests were used, according to the type of comparison, with  = 0.05. 
  
  
RESULTS 
Patient Demographics  
From the 38 patients that fitted the inclusion criteria’s 15 were women and 23 were men. The median age (at 
time of hepatic resection) was 64.32 as described in Table 1 (range 40 to 85), 14 were age 70 or older.  
Primary Lesion 
As presented in Table 1, 28 patients had their primary lesions in the colon. The majority, 52.6 %, had LCC, 
followed by rectal disease (26.3%) and RCC, (21.1%). Patients with RCC presented mean age of 73.38, versus 62.95 
in LCC and 59.8 in rectum. In 20 patients, 47.5%, the primary tumour was associated with regional lymph node 
metastases (3 in RCC, 11 in LCC and 6 in rectum). The primary tumour was associated with synchronous hepatic 
metastases in half of the patients (2 RCC, 10 in LCC and 7 in rectum) and in 23.7% of the patients within less than a 
year. Duo to occlusion (4) or perforation (2), six patients were submitted to urgent colon resection surgery. 
Adjuvant chemotherapy, after the primary tumour resection, was given to all patients but seven, one due to 
comorbidities and in other three because of the delayed of oncological consultation after primary tumour resection. 
No explanation was found in the other three. 
Histopathology 
 In seven patients’ histology of the primary tumour was not accounted for, since surgery was performed in the 
exterior, and therefore could not be access through the Hospital´s database. In this cohort, 75% of patients presented 
primary tumours that penetrated through the muscularis propria (T3). A majority of patients, 52.6%, presented positive 
lymph nodes (N1 or N2), however it should be accounted that 25.7% of the patients had less than 12 lymph nodes 
removed, which could underestimate this percentage. Results are presented in Table 1. Interestingly enough, in all 6 
patients subject to urgent colon resection complete lymphadenectomy was performed. Invasion of the visceral 
peritoneum was present in 5 patients, 4 in LCC and 1 RCC. 
 In 13 patients KRAS mutation was searched, five of them turn out positive, but in only two biologic agents 
were used. 
Neoadjuvant systemic and local therapy 
There were not used local therapies in these patients. Sixteen patients received neoadjuvant chemotherapy 
(42.11%), twelve presented synchronous hepatic metastases and in the other four cases chemotherapy was used to turn 
the hepatic lesions resectable. The neoadjuvant chemotherapy scheme more often used was FOLFOX or FOLFIRI (10 
  
of 16) often associated in biologic agents, when more than four hepatic lesions or bilobular disease was present. Only 
in three people capecitabine was administer and, in one patient, irinotecan was associated.  
Liver Tumour 
 The median number of liver metastases was 3 (range 1 to 15). Single liver tumour was present in seventeen 
patients (almost 45%). Generally speaking 78.9% present less than 5 liver metastases, 10.5% between 5 and 10 and 
10.5% over 10 hepatic metastases. The mean size of the biggest metastases was 3 cm (range 0.6 and 6) and only 4 
patients presented tumours larger than 5 cm. 
CEA levels 
 Preoperative CEA levels was not available in nine patients. Overall, 63.3% present levels under 10 ng/dL, and 
20% levels over 30 ng/dL. The mean CEA levels was 95.93 ng/dL, although it should be stated that tree patients 
presented values of 442.2, 739 and 1411.8 ng/dL, which can misrepresent this cohort. 
Surgical Resections 
 First and second liver resections performed are described in Table 2. Complete or extended lobectomy were 
complemented with liver metastasectomy in 28.9% of cases. On average two and half hepatic segments were resected, 
range 1 to 6. Ten patients were submitted to new hepatic resection, in this group, one patient underwent radioablation 
in association to liver resection. No other complementary technics were used. 
Simultaneous resection of the primary tumour was performed in five patients, 13.16%, and two patients 
underwent liver resection prior primary tumour resection (reverse approach). In seventeen patients clamping of the 
hepatic pedicle was performed. After initial hepatic resection, new hepatic resection was performed in 10 patients 
(26.32%). Two stage hepatectomy was executed in three patients, these patients presented multiple metastases with 
bilobular disease.  
Only one patient was treated with other local technics combined with hepatic surgery (radioablation), after 
intra-hepatic recurrence.  
Perioperative Results 
 Mean hospital stay was 11 days (range 5 to 47). Five patients required perioperative blood transfusion. Of the 
38 patients, four of them had post-operative complications, 10.56%. Two developed intra-abdominal abscess 
collections, one of them resolved with percutaneous drainage, whereas for the other one new surgical approach was 
needed and a drain was left in place. Other one developed atrial fibrillation being successfully treated with amiodaron. 
  
As for the last developed sepsis and exploratory laparotomy was required and although the source was not to be 
discovered during the procedure the patient had a following good recovery. 
Adjuvant therapies 
 Only 3 patients, 7.89%, did not receive adjuvant chemotherapy. Two presented a single hepatic lesion and the 
other three lesions but less than 0.6cm. In ten patients FOLFOX was used isolated, and in three patients’ bevacizumab 
or cetuximab was co-administered, six patients used FOLFIRI, one of them simultaneously with bevacizumab, one 
used irinotecan plus cetuximab, another one panitumumab, four XELOX and eight capecitabin alone.  
Follow-up 
After discharge, patients were reviewed after, first postoperative month and every 3 months in the first year, 
with evaluation of tumour markers (CEA), liver function tests, abdominal and chest CT scans performed after 6 and 
12 months. After 3 years of follow up with no recurrences, annual follow-up was considered, as well as discharged to 
family doctor after 5/6 years. Discontinuation of the treatment was decided in the absence of any persistent or recurrent 
tumour. 
Time recurrence 
 Of the 38 patients, 18 patients (47.37%) did not relapse and 20 patients relapsed within 19.45 months after 
hepatic surgery (range 3 to 39). Overall there was no statistical difference in age, gender, histopathology from the 
primary tumour, time of hepatic metastases and characteristics (size, number and localization), preoperative CEA 
levels or bilobular hepatic disease. However, two variables presented statistical significance (p <0.05) as is presented 
in Table 1. In this sample, early relapse was present only in those with LCC (p< 0.05). All R1 patients presented late 
relapse. However, late relapse was more frequent in patients with negative surgical margins (78.6% versus 21.4%, p 
< 0.043).  
 No relapse was found after 39 months. 
Disease free Survival 
Hepatic lesions were the only variables that appear to have statistical significance (p < 0.05), as observed in 
Table 3. Patients with less than 5 hepatic metastases had at least double time DFS (median of 86 months versus 41.5 
and 22). Although, timing of hepatic metastases, hepatic size metastases and surgical margins do not present statistical 
significance in this cohort, this should be confirmed with a greater size sample. Early metachronous hepatic metastases 
appear to have higher DFS then synchronous and late metachronous, median 105. 81 and 77, respectively (p < 0.061). 
  
The presence of hepatic metastases with less than 5 cm looks to enhance DFS when compared to those larger than 5 
cm (median 82 months versus 43.5 months, p < 0.61). Finally, patients with negative surgical margins present a median 
DFS of 82.5 months, whereas patients with positive margins present only 18 months (p < 0.66). 
Twenty-seven patients are presently in remission (71.05%).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
DISCUSSION 
Given the nature of the present study, several problems should be pointed out. This is a retrospective study 
which conditioned the collection of data, namely, some of the variables studied were non-existent or even incoherent, 
and therefore could not be used. Also, in the absent of a control group, patients that have died before the 5-year follow 
up, the factors in lighted in this study cannot be determined as prognostic factors and considered only associated 
factors, given that certain characteristics could be inherent to the present population with CRC stage IV. 
In this study, it is estimated an 31.7% survival rate of at 5-year follow up, 38 patients of 120. Nevertheless, it 
should be stated that 3 patients were excluded due to extra-hepatic disease at diagnoses, therefore a 34.2% survival 
would be more accurate. There was no significant difference between gender or age regarding relapse as some studies 
agree 13,29. Still, elderly appear to present worse outcome 30. 
Statistical significance was found in primary tumour localization. Patients with LCC were the only ones 
associated with early relapse (p = 0.05). Is it then correct to assume, that patients with early relapse with RCC or rectal 
cancer present a survival of less than 5 years? Many studies report worse prognosis and survival for those with RCC 
when compare to LCC, not only due histopathologic characteristic but to late clinical presentation and different 
metastatic sites 31–33. Also RCC seems associated more frequently to female gender and older patients 31–33. And it 
comes to no surprise that rectum cancer presents worse outcomes, earlier recurrence and worse OS even in the absence 
of hepatic metastases 34.  
Although, in general, histopathology differences are presented as a factor to worst prognosis, in this study was 
difficult to evaluate the impact of KRAS mutation since less than half of the patients had KRAS mutation searched. 
Presently it is stablished that RAS testing should be carried out in all patients with CRLM 5. KRAS mutation usually 
presents higher rates in RCC 32, and it´s been described that their presence can even decrease survival in 20% 35.  
Positive lymph nodes did no correlate to recurrence, as some stat in the literature 36,37.  Regardless, others 
considered their presence no only an important prognostic factor for recurrence but also for OS, 13,29, thus being 
included as variables for predicting scores for recurrence or survival. Positive lymph nodes are more specifically 
associated with early recurrence 38.   
Timing of hepatic metastases was defined according to a multidisciplinary international consensus. 20. In this 
cohort synchronous CRLM was present in half of the patients, and although it is known to present poor prognostic, it 
did not appear to relate to early recurrence. Moreover, according to several specialists consensus synchronous CRLM 
are associated with worse prognosis, especially when compared to late metachronous 5,20. Curious enough in the 
  
present study, not only early metachronous presented a higher DFS, synchronous metastases surpassed late 
metachronous, without reaching statistical significance, which comes to an agreement in some studies that timing of 
hepatic metastases do not affect OS or DFS 14. However, comparison to those deceased before 5year follow up would 
be require to encounter a more reliable conclusion.  
Number and size of hepatic metastases has been considered an important factor in predicting recurrence and 
OS, even though the exact size and number are still debateable. In the present study no statistical significance was 
found in CRLM characteristics regarding recurrence, as also described in some studies 27,39 or regarding solely size 38. 
However most studies included over 1 or 3 hepatic metastases as a predicting factor for recurrence 13,30,38. But a higher 
DFS was seen when less than 5 hepatic lesions were present, conduction to at least double time disease free (median 
of 86 months versus 41.5 and 22 (p < 0.033).  
As for CEA levels two things should be pointed out in the present study, in 8 patients CEA levels perioperative 
were not available, thus diminishing sample size, and in 16 of them neoadjuvant QT was used prior surgery that 
influence their value. So even if in a hand full of cases increased CEA levels indicted a recurrence, as found in literature 
28, this factor was not statistically associated with recurrence or DFS.  
The surgical approach although described was not statistically studied. It is described in the literature that 
simultaneous resection in synchronous CRLM is safe and associated with decrease time in hospital admission, 
however this should not be applied in those intended to major hepatectomy and resection of over 3 segments duo to 
higher risk of complications, 40,41. Other studies suggest that the classical approach was in general associated with 
better OS and DFS 42. Also, in this study patients who were submitted to two stage hepatectomy presented bilobular 
disease and multiple metastases, and it has been showed that even in the presence of extensive metastatic disease, 
those who complete two stage hepatectomy can achieve comparable OS as those submitted to Classical approach and 
one stage hepatectomy regardless of recurrence 43.  
A secondary procedure was performed in 10 patients and no more than 3 segments were removed. This is 
consistent with former studies that acknowledge major hepatectomy as being less frequent in a second hepatectomy 
44,45. Moreover, a secondary hepatectomy may well be associated with better OS 45. 
As described, only one patient was subjected to other local technics, specifically radioablation, combined with 
liver surgery. NCCN guidelines suggests the use of radioablation only in those with recurrent small hepatic metastases 
with adequate margins, 4, adding the existence of limited data. Interestingly enough, studies have shown that 
radioablation is associated with increase hepatic recurrence when compared to surgery alone 27,46. 
  
In the present study statistical significance was obtained in surgical margins. Positive margins were associated 
with early recurrence, although negative margins presented a majority in this group. Most studies support that R0 
margins are not only associated with less recurrence but also to an increase in OS 27,30,38,47. However, some like Hass 
et al, don´t agree that R1 margins have impact on OS 48. Even thought, surgical margins did not reach a statistical 
significance in DFS, p < 0.066, a propensity score matching analysis concluded that R1 margins are still an impacting 
factor in OS and DFS, even when recurrence has been balanced 49. 
As a final remark, twenty patients of the present study presented relapse within 19.45 months after hepatic 
surgery (range 3 to 39). Twenty-seven patients are presently in remission (71.05%). Even though we analysed those 
with 5-year follow up we have patients that actually present till 10 years (120 months) survival after hepatic resection. 
So in some we can agree with studies that stat that patients that do not present any recurrence before 5-years that they 
are “cured” 50, seen no patients in this study present relapse after 60 months. However, this should be pursued in 
patients with less than 5-years survival.  
 
  
  
CONCLUSION 
Summarizing, more than half of patients, with 5-year survival, and LCC have faster relapse. Although DFS 
was similar independently of the site of the primary tumour. Also, DFS is best for patients with less than 5 lesions. In 
a greater size sample timing, number, size of hepatic metastases and surgical margins should be study as possible 
factors that could enhance DFS, even though in this cohort statistical significance was not reached. 
The existence of several discrepancies in the nomenclature regarding the factors associated with recurrence 
and OS calls for the performance of studies at greater scale, namely in different specialized centers. Is it not wise to 
question that, since studies are being performed in different populations, the same factor could be more determinant 
in some populations and have less impact in others. Additionally, the same factors could be misevaluated taking into 
account distinct cut-offs. There is no surprise that, consensus prevenient from specialist panels pronounces that 
treatment and surgical approach should always be taken into consideration by multidisciplinary teams that considered 
the inherent clinical characteristic of the patient itself.   
This study should be criticized duo to small size sample and the lack of comparation with patients’ deceased 
before 5-year follow up. However, this could be the start of a large-scale study that could not only turn to a 
development of a solid score but also have greater implication as to the choosing of more adequate patients for surgery 
and the choosing of those in which a more aggressive therapy should be performed, for starts in CHSJ.  
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Figure 1: Diagram representing patient selection from the Department´s Database. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patients submitted to resection of CRLM were 
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n = 120
n = 43
n = 40
n = 38
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than 5-year follow up 
Exclusion of patients with benign 
hepatic lesions 
Exclusion of patients with extra-
hepatic metastases at diagnosis 
Exclusion of patients with less 
than 5-year survival 
  
TABLE 1: FACTORS ASSOCIATED WITH RECURRENCE 
 Total sample 
(n=38) 
No-relapsed 
(n=18) 
Early Recurrence 
(n=15) 
Late Recurrence 
(n=5) 
P (α= 0.05) 
Age (years) 64.32±11.00 
(60.70 – 67.93) 
68.11±9.36 (63.46 
– 72.76) 
61.07 ±12.58 
(54.10 – 68.03) 
60.40±8.39 (49.99 
– 70.81) 
0.129 
Gender (%) 
Male 
Female 
 
60.5 
39.5 
 
61.1 
38.9 
 
 
53.3 
46.7 
 
80 
20 
 
0.571 
Primary tumour 
localization 
RCC 
LCC 
Rectum 
 
 
 
21.1 
52.6 
26.3 
 
 
27.8 
44.4 
27.8 
 
 
20.0 
46.7 
33.3 
 
 
0 
100* 
0 
 
 
 
 
*<0.05 
T (%), n=36 
2 
3 
4 
 
11.1 
75 
13.9 
 
11.8 
70.6 
17.6 
 
14.3 
78.6 
7.1 
 
0 
80 
20 
 
 
0.820 
 
N (%) 
0 
1 
2 
 
47.4 
36.8 
15.8 
 
55.6 
27.8 
16.7 
 
40 
46.7 
13.3 
 
40 
40 
20 
 
 
0.842 
Lymphadenectomy 
(n=35) 
Non complete 
Complete 
 
 
25.7 
74.3 
 
 
27.8 
72.2 
 
 
25 
75 
 
 
20 
80 
 
 
0.938 
Visceral 
peritoneum 
invasion (n=31) 
No 
Yes 
 
 
 
83.9 
16.1 
 
 
 
82.4 
17.6 
 
 
 
90 
10 
 
 
 
75 
25 
 
 
 
0.764 
 
Timing hepatic 
metastases (%) 
Synchronous 
Metachronous 
Early  
Late 
 
 
50 
 
23.7 
26.3 
 
 
44.4 
 
33.3 
22.2 
 
 
53.3 
 
20 
26.7 
 
 
60 
 
0 
40 
 
 
 
0.610 
Hepatic lesions 
number (%) 
<5 
5-10 
>10 
 
 
78.9 
10.5 
10.5 
 
 
88.9 
5.6 
5.6 
 
 
73.3 
13.3 
13.3 
 
 
60 
20 
20 
 
 
 
0.656 
Hepatic size 
metastases (%, 
n=37) 
<5 
5-10 
 
 
 
89.2 
10.8 
 
 
 
88.9 
11.1 
 
 
 
92.9 
7.1 
 
 
 
80 
20 
 
 
0.728 
Pre-op CEA levels 
(n=30) 
<10 
10-30 
>30 
 
 
63.3 
16.7 
20.0 
 
 
56.3 
25 
18.8 
 
 
77.8 
0 
22.2 
 
 
60 
20 
20 
 
 
0.615 
Bilobolar hepatic 
metástases (%, 
n=37) 
Absent 
Present 
 
 
 
64.9 
35.1 
 
 
 
72.2 
27.8 
 
 
 
57.1 
42.9 
 
 
 
60 
40 
 
 
 
0.655 
 
  
ASA (%) 
I 
II 
III 
 
65.8 
13.2 
21.1 
 
61.1 
16.7 
22.2 
 
73.3 
6.7 
20 
 
60 
20 
20 
 
0.900 
 
 
Surgical margins 
(n=37) 
Negative 
Positive 
 
 
91.9 
8.1 
 
 
100 
0 
 
 
78.6* 
21.4* 
 
 
100 
0 
 
 
*0.043 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
TABLE 2: SURGICAL PROCEDURES 
 Primary Liver procedure (n) Secondary Liver procedure (n) 
Metastasectomy 11 1 
Segmentectomy 7 3 
Bisegmentectomy 6 4 
Trisegmentectomies 5 2 
Four segments resected 3 0 
Five segments resected 6 0 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
TABLE 3: FACTORS ASSOCIATED WITH DISEASE FREE SURVIVAL 
 Disease free survival 
(n=38, months) 
Median(P5-P95) 
P 
 
Total 
 
82 (9.65 – 127.10) 
 
Sex  
Male 
Female 
 
82.00 (4.4-128) 
82.00 (11 – 127) 
 
0.834 
Primary tumour localization 
RCC 
LCC 
Rectum 
 
 
77 (19 – 110) 
85.5 (3.35-128.9) 
81.5 (15-112.2) 
 
 
0.798 
T, (n=36) 
2 
3 
4 
 
80.5 (6,1-103.5) 
86 (6.2-128.2) 
72 (10-102) 
 
0.611 
 
 
N 
0 
1 
2 
 
82 (3-127) 
80 (15-122.5) 
88,5 (10-117) 
 
0.897 
Lymphadenectomy (n=35) 
Incomplete 
Complete 
 
81.5 (5.45-125.15) 
89 (15-125.5) 
 
0.213 
Visceral peritoneum invasion (n=31) 
No 
Yes 
 
84 (12.4-128.3) 
72 (10-102) 
 
0.295 
 
Timing hepatic metastases (%) 
Synchronous 
Metachronous 
Early  
Late 
 
81 (12.75-127.9) 
 
105 (22-121) 
77 (11-125.1) 
 
 
0.061 
Hepatic lesions number (%) 
<5 
5-10 
>10 
 
86 (12.75-127.9) 
22 (11-85.5) 
41.5 (3-70.75) 
 
*0.033 
Hepatic size metastases (%, n=37) 
<5 
5-10 
 
82 (10.70-127.60) 
43.5 (3-96.75) 
 
0.061 
Pre-op CEA levels (n=30) 
<10 
10-30 
>30 
 
88 (10-124) 
82 (74-111.5) 
77 (3-86.75) 
 
0.412 
Bilobolar hepatic metástases (%, n=37) 
Absent 
Present 
 
84 (11.25-127.75) 
81 (3-127) 
 
0.408 
ASA (%) 
I 
II 
III 
 
83 (10.3-128.4) 
80 (17-110) 
77.5 (3-87.5) 
 
 
0.507 
 
Surgical margins (n=37) 
Negative 
Positive 
 
82.5 (8.25-127.5) 
18 (17-18) 
 
0.066 
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society or meeting (with full details). 
  
Abstract 
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state why the study was done, the main aim and the nature of the study (randomized clinical    trial, 
retrospective review, experimental study etc). Methods: describe patients, laboratory material and 
other methods used. Results: state the main findings, including important numerical values. 
Discussion: state the main conclusions, highlighting controversial or unexpected observations. 
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designed to capture the attention of a wide readership. Graphical abstracts should be submitted as a 
separate file in the online submission system. Image size: Please provide an image with a minimum 
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10 000. Use SI units (International System of Units) except for the measurement of blood pressure 
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Statistics and design 
Set out clearly the objectives of the study; identify the primary and secondary hypotheses, the chosen 
end-points and justify the sample size with a power calculation. 
 
Clearly describe methods used for analysis; methods not in common usage should be referenced. 
Report results of statistical tests by stating the value of the test statistic, the number of degrees   of 
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For nominal data with denominators greater than 50, percentages should be given to 1 decimal place. 
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